DZ2665A1 - Conjugués utiles pour le traitement du cancer de la prostate. - Google Patents

Conjugués utiles pour le traitement du cancer de la prostate.

Info

Publication number
DZ2665A1
DZ2665A1 DZ980275A DZ980275A DZ2665A1 DZ 2665 A1 DZ2665 A1 DZ 2665A1 DZ 980275 A DZ980275 A DZ 980275A DZ 980275 A DZ980275 A DZ 980275A DZ 2665 A1 DZ2665 A1 DZ 2665A1
Authority
DZ
Algeria
Prior art keywords
treatment
prostate cancer
conjugates useful
conjugates
useful
Prior art date
Application number
DZ980275A
Other languages
English (en)
French (fr)
Inventor
Stephen F Brady
Feng Dong-Mei
Victor M Garsky
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9804399.5A external-priority patent/GB9804399D0/en
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Application granted granted Critical
Publication of DZ2665A1 publication Critical patent/DZ2665A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
DZ980275A 1997-12-02 1998-11-30 Conjugués utiles pour le traitement du cancer de la prostate. DZ2665A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6711097P 1997-12-02 1997-12-02
GBGB9804399.5A GB9804399D0 (en) 1998-03-02 1998-03-02 Conjugates useful in the treatment of prostate cancer

Publications (1)

Publication Number Publication Date
DZ2665A1 true DZ2665A1 (fr) 2003-03-22

Family

ID=26313204

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ980275A DZ2665A1 (fr) 1997-12-02 1998-11-30 Conjugués utiles pour le traitement du cancer de la prostate.

Country Status (26)

Country Link
US (2) US20060148718A1 (ko)
EP (1) EP1036093A1 (ko)
JP (1) JP2001525337A (ko)
KR (1) KR100580137B1 (ko)
CN (1) CN1181092C (ko)
AR (1) AR016427A1 (ko)
AU (1) AU744652B2 (ko)
BG (1) BG65486B1 (ko)
BR (1) BR9815116A (ko)
CA (1) CA2311615A1 (ko)
DZ (1) DZ2665A1 (ko)
EA (1) EA002745B1 (ko)
EE (1) EE200000333A (ko)
HR (1) HRP20000367A2 (ko)
HU (1) HUP0100350A3 (ko)
ID (1) ID24735A (ko)
IL (1) IL136167A0 (ko)
IS (1) IS5502A (ko)
NO (1) NO20002804L (ko)
NZ (1) NZ504615A (ko)
PE (1) PE20000009A1 (ko)
PL (1) PL197006B1 (ko)
SK (1) SK8282000A3 (ko)
TR (1) TR200002260T2 (ko)
TW (1) TW577897B (ko)
WO (1) WO1999028345A1 (ko)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000033888A2 (en) * 1998-12-11 2000-06-15 Coulter Pharmaceutical, Inc. Prodrug compounds and process for preparation thereof
GB9924759D0 (en) * 1999-10-19 1999-12-22 Merck Sharp & Dohme Process for preparing peptide intermediates
US7842581B2 (en) 2003-03-27 2010-11-30 Samsung Electronics Co., Ltd. Methods of forming metal layers using oxygen gas as a reaction source and methods of fabricating capacitors using such metal layers
JP2010536790A (ja) 2007-08-17 2010-12-02 パーデュー・リサーチ・ファウンデーション Ｐｓｍａ結合性リガンド−リンカー結合体及び使用方法
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
US9371362B2 (en) * 2012-08-15 2016-06-21 Visen Medical, Inc. Prostate specific antigen agents and methods of using same for prostate cancer imaging
WO2014074218A1 (en) * 2012-11-12 2014-05-15 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
BR112015011118B1 (pt) 2012-11-15 2022-12-13 Endocyte, Inc Conjugado; composição farmacêutica; e uso de um conjugado
WO2014178839A1 (en) 2013-04-30 2014-11-06 Hewlett-Packard Development Company, L.P. Memory access rate
RS65324B1 (sr) 2013-10-18 2024-04-30 Novartis Ag Obeleženi inhibitori membranskog antigena specifičnog za prostatu (psma), njihova upotreba kao agenasa za snimanje i farmaceutskih agenasa za lečenje karcinoma prostate
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
CN116635054A (zh) 2020-12-22 2023-08-22 科比欧尔斯公司 包括四肽部分的化合物
WO2022167664A1 (en) 2021-02-07 2022-08-11 Cobiores Nv Compounds comprising a tetrapeptidic moiety

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203898A (en) * 1977-08-29 1980-05-20 Eli Lilly And Company Amide derivatives of VLB, leurosidine, leurocristine and related dimeric alkaloids
US4296105A (en) * 1978-08-03 1981-10-20 Institut International De Pathologie Cellulaire Et Moleculaire Derivatives of doxorubicine, their preparation and use
US4719312A (en) * 1978-10-02 1988-01-12 Merck & Co., Inc. Lysosometropic detergent therapeutic agents
US4376765A (en) * 1980-03-31 1983-03-15 Institut International De Pathologie Cellulaire Et Moleculaire Medicaments, their preparation and compositions containing same
US4639456A (en) * 1980-06-10 1987-01-27 Omnichem S.A. Vinblastin-23-oyl amino acid derivatives
GR81790B (ko) * 1983-04-29 1984-12-12 Omnichem Sa
FR2546163B1 (fr) * 1983-05-16 1987-10-09 Centre Nat Rech Scient Nouveaux derives acyles hydrosolubles de peptides ou d'amino-acides, leur preparation et leur application
FR2626882B1 (fr) * 1988-02-08 1991-11-08 Ire Celltarg Sa Conjugues de derives de vinca comportant une chaine detergente en position c-3
US5391723A (en) * 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
EP0647450A1 (en) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
US5599686A (en) * 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides
US6143864A (en) * 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
JP2000506494A (ja) * 1995-10-18 2000-05-30 メルク エンド カンパニー インコーポレーテッド 良性前立腺過形成の治療に有用な複合体
US5998362A (en) * 1996-09-12 1999-12-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
WO1998010651A1 (en) * 1996-09-12 1998-03-19 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
HRP970566A2 (en) * 1996-10-30 1998-08-31 Jones Deborah Defeo Conjugates useful in the treatment of prostate canser

Also Published As

Publication number Publication date
CN1284086A (zh) 2001-02-14
US20070021350A1 (en) 2007-01-25
AU1612399A (en) 1999-06-16
NO20002804L (no) 2000-07-21
TR200002260T2 (tr) 2000-12-21
PL197006B1 (pl) 2008-02-29
CA2311615A1 (en) 1999-06-10
AU744652B2 (en) 2002-02-28
NZ504615A (en) 2003-05-30
EE200000333A (et) 2001-08-15
KR100580137B1 (ko) 2006-05-16
ID24735A (id) 2000-08-03
HUP0100350A3 (en) 2001-09-28
AR016427A1 (es) 2001-07-04
EA200000603A1 (ru) 2000-12-25
PE20000009A1 (es) 2000-01-27
BG104563A (en) 2001-04-30
SK8282000A3 (en) 2000-11-07
JP2001525337A (ja) 2001-12-11
BR9815116A (pt) 2000-10-10
CN1181092C (zh) 2004-12-22
US20060148718A1 (en) 2006-07-06
KR20010032687A (ko) 2001-04-25
BG65486B1 (bg) 2008-09-30
PL340768A1 (en) 2001-02-26
WO1999028345A1 (en) 1999-06-10
EP1036093A1 (en) 2000-09-20
NO20002804D0 (no) 2000-05-31
TW577897B (en) 2004-03-01
IS5502A (is) 2000-05-19
IL136167A0 (en) 2001-05-20
HUP0100350A2 (hu) 2001-08-28
EA002745B1 (ru) 2002-08-29
HRP20000367A2 (en) 2000-12-31

Similar Documents

Publication Publication Date Title
FR15C0070I2 (fr) Composes heteroaromatiques azotes pour le traitement des maladies de cancer
DZ2333A1 (fr) Conjugues utiles au traitement du cancer de la prostate
FR07C0046I2 (fr) Beta-l-2'-desoxy-nucleosides pour le traitement de l'hepatite b
ITMI990375A1 (it) Trattamento del cancro co epotiloni
PT1187632E (pt) Tratamento com anticorpos anti-erbb2
FR2717848B1 (fr) Panneau pour la réalisation de bassins de rétention.
EP0926955A4 (en) Conjugates useful in the treatment of prostate cancer
CH1143977H1 (fr) 2-Oxy-benzoxazine-4-ones destinees au traitement de l'obesite
DZ3014A1 (fr) Médicaments pour le traitement de l'hypertension.
DZ2665A1 (fr) Conjugués utiles pour le traitement du cancer de la prostate.
IS5035A (is) Aðferðir til varnar gegn brjóstakrabbameini
DK0972024T4 (da) Tumorsuppressor designeret TS10Q23.3
ITTO940748A0 (it) Condotto protesico particolarmente per il trattamento di patologie cardiovascolari.
DZ2012A1 (fr) Benzamides pour le traitement de dégénérescences neurologiques.
PT1043025E (pt) Tratamento de carcinoma da celula renal
EA199900298A1 (ru) Средство для воздействия на организм
ZA9810974B (en) Conjugates useful in the treatment of prostate cancer
ZA200203166B (en) Treatment of cancer.
HK1050533A1 (en) Substituted pyrroles as antiproliferative agents for the treatment of cancer.
FR2785545B3 (fr) Calecon pour le traitement topique de la cellulite
AU7130696A (en) Combination of beta-interferon for the treatment of prostate cancer
ZA979655B (en) Conjugates useful in the treatment of prostate cancer.
ES1031709Y (es) Prenda interior.
HK1034979A1 (en) Conjugates useful in the treatment of prostate cancer.
ES1035863Y (es) Panty bipieza.